Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zevra Therapeutics

7.87
+0.08001.03%
Post-market: 7.870.00000.00%16:05 EDT
Volume:363.46K
Turnover:2.90M
Market Cap:430.33M
PE:-3.45
High:8.08
Open:7.82
Low:7.82
Close:7.79
Loading ...

Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million

Dow Jones
·
27 Feb

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA) and Venus Concept (VERO)

TIPRANKS
·
27 Feb

Zevra Therapeutics Enters Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher for $150 Million

THOMSON REUTERS
·
27 Feb

Press Release: Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Dow Jones
·
27 Feb

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

GlobeNewswire
·
26 Feb

Zevra to Participate at Upcoming Investor Conferences

GlobeNewswire
·
25 Feb

Zevra Therapeutics (ZVRA) Gets a Buy from Roth MKM

TIPRANKS
·
10 Feb

Zevra Therapeutics price target raised to $21 from $20 at Guggenheim

TIPRANKS
·
04 Feb

Positive Signs As Multiple Insiders Buy Zevra Therapeutics Stock

Simply Wall St.
·
17 Jan

Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long

Simply Wall St.
·
27 Dec 2024

Zevra Therapeutics to Join Nasdaq Biotechnology Index

MT Newswires Live
·
17 Dec 2024

Zevra Therapeutics to Be Added to Nasdaq Biotechnology Index (Nasdaq: Nbi) Effective December 23, 2024

THOMSON REUTERS
·
17 Dec 2024

BRIEF-Zevra Therapeutics Announces Organizational Changes

Reuters
·
07 Dec 2024

Zevra Therapeutics Restructures to Focus on Rare Diseases

TIPRANKS
·
07 Dec 2024

Zevra Therapeutics announces departure of CDO Christal Mickle, CSO Sven Guenther

TIPRANKS
·
07 Dec 2024

Zevra Therapeutics Inc - to Close Laboratory Facilities in Iowa and Virginia

THOMSON REUTERS
·
07 Dec 2024

Zevra Therapeutics Announces Organizational Changes

THOMSON REUTERS
·
07 Dec 2024

Zevra Therapeutics Inc - Consolidates Development and Scientific Functions Under Cmo Adrian Quartel

THOMSON REUTERS
·
07 Dec 2024

Zevra Therapeutics Inc - Christal M.m. Mickle, Chief Development Officer, and Sven Guenther, Ph.d., Chief Scientific Officer, to Depart Co

THOMSON REUTERS
·
07 Dec 2024

Zevra Therapeutics Inc - Eliminates Positions in Chemistry, Manufacturing and Controls and Clinical Development

THOMSON REUTERS
·
07 Dec 2024